quinoxalines has been researched along with Nervous System Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beard, JD; Davis, RE; Hendrick, JP; Lee, T; Li, P; Mates, S; Peng, Y; Robichaud, AJ; Snyder, GL; Tomesch, J; Vanover, KE; Wennogle, LP; Yao, W; Zhang, Q; Zhu, H | 1 |
| Niu, L | 1 |
| Ahmed, A; Ahmed, E; Ballabh, P; Dohare, P; Kayton, R; Mongin, AA; Ortega, JA; Schober, AL; Ungvari, Z; Yadala, V; Zia, MT | 1 |
| Nadeem, SS; Pirmoradi, P; Roshan, S | 1 |
| Dupont, P; Gillet, C; Guerin, M; Guillaumin, C; Kalamarides, S; Larinier, E; Meignan, C; Moreau, A; Perriot, J | 1 |
| Higashi, S; Hioki, K; Kasim, N; Kurotani, T; Molnár, Z | 1 |
| Barbe, ME; Carlsen, JO; Kwon, YH; Scott, WE; Zabriskie, NA | 1 |
| Hayakawa, T; Kinoshita, A; Kohmura, E; Yamada, K | 1 |
8 other study(ies) available for quinoxalines and Nervous System Disorders
| Article | Year |
|---|---|
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biological Availability; Drug Discovery; Electroshock; Indicators and Reagents; Male; Mental Disorders; Nervous System Diseases; Quinoxalines; Quipazine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recombinant Proteins; Schizophrenia; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2014 |
AMPA receptor inhibitors for the treatment of neurological disorders.
Topics: Aptamers, Nucleotide; Excitatory Amino Acid Antagonists; Humans; Nervous System Diseases; Quinoxalines; Receptors, AMPA | 2014 |
AMPA-Kainate Receptor Inhibition Promotes Neurologic Recovery in Premature Rabbits with Intraventricular Hemorrhage.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Calcium Signaling; Cerebral Ventricles; Cytokines; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Glycerol; Hemorrhage; Humans; Leukoencephalopathies; Male; Nervous System Diseases; Nitriles; Pregnancy; Pyridones; Quinoxalines; Rabbits; Receptors, AMPA; Recovery of Function | 2016 |
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression.
Topics: Adult; Alcoholism; Benzazepines; Depressive Disorder, Major; Humans; Male; Mental Disorders; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
[Tolerability profile of varenicline in current medical practice].
Topics: Adult; Benzazepines; Female; France; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Metabolic Diseases; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Skin Diseases; Smoking; Varenicline | 2010 |
Functional thalamocortical synapse reorganization from subplate to layer IV during postnatal development in the reeler-like mutant rat (shaking rat Kawasaki).
Topics: Action Potentials; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Axons; Cell Lineage; Cellular Senescence; Cerebral Cortex; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Microscopy, Confocal; Nervous System Diseases; Neurons; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Mutant Strains; Somatosensory Cortex; Synapses; Thalamus | 2005 |
Apparent central nervous system depression in infants after the use of topical brimonidine.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System; Follow-Up Studies; Glaucoma; Humans; Infant; Infant, Newborn; Intraocular Pressure; Male; Nervous System Diseases; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 1999 |
Neurotoxicity caused by glutamate after subcritical hypoxia is prevented by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX): an in vitro study using rat hippocampal neurons.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Female; Glutamates; Glutamic Acid; Hippocampus; Hypoxia; Nervous System Diseases; Neurons; Pregnancy; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, AMPA; Receptors, Kainic Acid; Receptors, Neurotransmitter | 1991 |